BAYZED HEALTH (02609), a leading cancer medical group in China, saw its stock price soar by 10.50% in intraday trading, reaching a new post-listing high. The surge comes on the heels of significant developments in cancer rehabilitation strategies and anticipation of the company's upcoming interim results.

The company recently collaborated with Peking University Third Hospital and other renowned tertiary hospitals across China to formulate the "Cancer Rehabilitation Expert Consensus (2025)." This consensus, published in the authoritative "Chinese Journal of Clinicians," introduces a groundbreaking "five major prescriptions" rehabilitation strategy. The new approach emphasizes comprehensive cancer rehabilitation, including pre-treatment prehabilitation, rehabilitation during treatment, and long-term care, with multidisciplinary teams at its core.

Adding to the positive sentiment, BAYZED HEALTH announced plans to convene a board meeting on August 28 to consider and approve its interim results. This upcoming financial disclosure has further fueled investor interest. As BAYZED HEALTH continues to strengthen its position in the cancer treatment market, operating eight hospitals across five provinces and municipalities, the market appears optimistic about the company's growth prospects and its potential to revolutionize cancer care in China.